IP Library Granted Patent US 11,357,802
Granted Patent B2
US 11,357,802 · App. 16/402,008 · Granted Jun 14, 2022

Oral delivery compositions for improved gut barrier protection and immunity in mammals

Inventors: Daniel J. DuBourdieu (Limerick, ME); Rajiv Lall (Menomonie, WI); Ajay Srivastava (Menomonie, WI)
Assignee: Vets Plus, Inc.
A61K35/742A23L33/135A23L33/155A23L33/175A61K9/0056A61K31/07A61K31/198A61K31/375A61P1/00A23V2002/00A23V2200/3202A23V2200/3204A23V2250/0606A23V2250/5034A23V2250/702A23V2250/708A23V2250/712A61K31/355
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,357,802
App. No.
16/402,008
Granted
Jun 14, 2022
Kind
B2
Abstract

Compositions containing probiotics and a nitric oxide precursor such as L-arginine to enhance nitric oxide production in animals and methods for improving immunity, gut barrier functions, and gut health and treating gastroenteritis and mucositis in animals using same.

Claims (20)

1. A method of improving gut health in an animal, the method comprising orally administering to an animal in need thereof a therapeutically effective amount of an oral ingestible composition, wherein: the composition comprises effective amounts of active ingredients; and the active ingredients comprise a probiotic and a nitric oxide precursor, and wherein the probiotic comprises Bacillus coagulans or Bacillus licheniformis.

2. The method of claim 1 , wherein the probiotic comprises a combination of Bacillus coagulans, Bacillus licheniformis , and Bacillus subtilis.

3. The method of claim 1 , wherein the probiotic is included in the composition in an amount from about 0.15% w/w to about 15% w/w.

4. The method of claim 1 , wherein the nitric oxide precursor comprises L-arginine.

5. The method of claim 1 , wherein the nitric oxide precursor is included in the composition in an amount from about 0.015% w/w to about 1.5% w/w.

6. The method of claim 1 , wherein the oral ingestible composition further comprises beta glucan.

7. The method of claim 1 , wherein the oral ingestible composition further comprises vitamin C, vitamin A, and vitamin E.

8. The method of claim 1 , wherein the oral ingestible composition further comprises a prebiotic.

9. The method of claim 1 , wherein the oral ingestible composition is in the form of a soft dough composition with the active ingredients evenly distributed throughout.

10. The method of claim 1 , wherein the oral ingestible composition is in the form of a dispersible powder.

11. The method of claim 1 , wherein the oral ingestible composition is in the form of a dispersible powder and is added to a foodstuff prior to the administering.

12. The method of claim 11 , wherein the foodstuff is a solid foodstuff.

13. The method of claim 1 , wherein the animal is an animal exhibiting detectable signs of stress.

14. The method of claim 1 , wherein the animal is an animal suffering from gastroenteritis.

15. The method of claim 1 , wherein the animal is an animal suffering from mucositis.

16. The method of claim 1 , wherein:

the nitric oxide precursor is L-arginine and is included in the composition in an amount from about 0.015% w/w to about 1.5% w/w;

the probiotic is included in the composition in an amount from about 0.15% w/w to about 15% w/w; and

the composition is administered to the animal in an amount from about 0.02 g/kg animal body weight/day to about 2 g/kg animal body weight/day for a period of at least two consecutive days.

17. The method of claim 1 , wherein the composition is administered in an amount and for a time effective to reduce a value of a parameter selected from the group consisting of phenol concentration and indole concentration in feces of the animal with respect to a value of the parameter in the feces of the animal not administered the oral ingestible composition but otherwise subjected to identical conditions.

Assignments (3)
ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Apr 18, 2022
From: MADISON CAPITAL FUNDING LLC
To: APOGEM CAPITAL LLC, AS SUCCESSOR AGENT
Reel/Frame 059724/0617 →
SECURITY INTEREST Recorded Feb 18, 2022
From: VETS PLUS, INC.
To: MADISON CAPITAL FUNDING LLC, AS AGENT
Reel/Frame 059047/0507 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2021
From: DUBOURDIEU, DANIEL J; LALL, RAJIV; SRIVASTAVA, AJAY
To: VETS PLUS, INC.
Reel/Frame 056992/0793 →
Continuity (2)
Provisional Application 62665900 · May 2, 2018
Related Publication 20190336546A1 · Nov 7, 2019